Fig 1.
Flow diagram of study selection.
Table 1.
Summary of basic characteristics and performance of studies included in meta-analysis.
Table 2.
Performance of single-gene stool DNA methylation biomarker tests.
Fig 2.
Summary estimates of SFRP1 and SFRP2.
(A) Summary estimates of SFRP1. hypermethylation in stool samples used for TP (CRC+ Adenoma) diagnosis. Red circles represent each study that was included in the meta-analysis. The size of each study is indicated by the size of the red circle. Error bars indicate the 95% confidence interval (CI). Positive LR: positive likelihood ratio, Negative LR: negative likelihood ratio, Diagnostic OR: diagnosis odd ratio, SROC curves: summary receiver operating characteristic curve. (B) Summary estimates of SFRP2. hypermethylation in stool samples used for TP (CRC+ Adenoma) diagnosis. Red circles represent each study that was included in the meta-analysis. The size of each study is indicated by the size of the red circle. Error bars indicate the 95% confidence interval (CI). Positive LR: positive likelihood ratio, Negative LR: negative likelihood ratio, Diagnostic OR: diagnosis odd ratio, SROC curves: summary receiver operating characteristic.
Table 3.
Performance of a certain gene in all single-gene stool-based DNA methylation biomarker tests included in this meta- analysis.
Fig 3.
Publication bias of studies in different categories.
CRC: colorectal cancer, TA: total adenoma, TP: total patients.
Fig 4.
Methylation of candidate genes in different categories.
Different genes are hypermethylated in development of CRC. CRC: colorectal cancer, AA: advanced-adenoma, NAA: non-advanced adenoma.